BRAF and melanoma: Furthermore, although PIK3CA mutations have not previously been reported as a cause of acquired resistance to BRAF inhibitors in melanoma or other malignancies, low PTEN expression and other PTEN alterations are associated with lower response rate and shorter progression-free survival in BRAF mutant melanoma patients treated with BRAF inhibitors[20,21].